38 Investor presentation First nine months of 2022 GLP-1 and SGLT-2i have been driv global diabetes care market Estimated global number of patients CAGR: +4% 192 million 218 million Estimated global di CAGR: +5 USD 47 billion 2018 Insulin 2021 2018 GLP-1 SGLT-2i DPP-4i T Note: GLP-1+basal insulin combination sales are included in insulin; Traditional OADs include metformin, SU and TZDs. CAGR: Comp Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP
Share
Download PDF file
